BSE Live
Oct 10, 16:01Prev. Close
1118.95
Open Price
1125.00
Bid Price (Qty.)
1126.55 (10)
Offer Price (Qty.)
1133.00 (2)
NSE Live
Oct 10, 15:56Prev. Close
1119.90
Open Price
1125.40
Bid Price (Qty.)
1130.30 (523)
Offer Price (Qty.)
0.00 (0)
Balance Sheet of Aurobindo Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
EQUITIES AND LIABILITIES | ||||||
SHAREHOLDER'S FUNDS | ||||||
Equity Share Capital | 58.08 | 58.59 | 58.59 | 58.59 | 58.59 | |
Total Share Capital | 58.08 | 58.59 | 58.59 | 58.59 | 58.59 | |
Reserves and Surplus | 20,476.03 | 19,664.23 | 17,855.58 | 17,058.75 | 15,866.02 | |
Total Reserves and Surplus | 20,476.03 | 19,664.23 | 17,855.58 | 17,058.75 | 15,866.02 | |
Total Shareholders Funds | 20,534.11 | 19,722.82 | 17,914.17 | 17,117.34 | 15,924.61 | |
NON-CURRENT LIABILITIES | ||||||
Long Term Borrowings | 400.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax Liabilities [Net] | 101.43 | 118.91 | 215.91 | 237.03 | 433.38 | |
Other Long Term Liabilities | 3.72 | 21.51 | 42.91 | 60.58 | 74.42 | |
Long Term Provisions | 53.30 | 46.00 | 87.31 | 5.03 | 0.00 | |
Total Non-Current Liabilities | 558.45 | 186.42 | 346.13 | 302.64 | 507.80 | |
CURRENT LIABILITIES | ||||||
Short Term Borrowings | 4,225.09 | 2,817.84 | 4,142.57 | 1,818.62 | 3,953.10 | |
Trade Payables | 1,787.42 | 1,789.23 | 2,202.32 | 1,661.15 | 2,060.95 | |
Other Current Liabilities | 386.64 | 619.64 | 298.80 | 597.84 | 631.53 | |
Short Term Provisions | 21.35 | 18.03 | 29.66 | 103.36 | 111.00 | |
Total Current Liabilities | 6,420.50 | 5,244.74 | 6,673.35 | 4,180.97 | 6,756.58 | |
Total Capital And Liabilities | 27,513.06 | 25,153.98 | 24,933.65 | 21,600.95 | 23,188.99 | |
ASSETS | ||||||
NON-CURRENT ASSETS | ||||||
Tangible Assets | 2,185.29 | 2,222.21 | 3,481.88 | 3,560.27 | 4,457.32 | |
Intangible Assets | 151.51 | 196.92 | 205.62 | 25.56 | 14.75 | |
Capital Work-In-Progress | 87.53 | 132.68 | 239.09 | 225.15 | 719.02 | |
Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Fixed Assets | 2,424.33 | 2,551.81 | 3,926.59 | 3,810.98 | 5,206.96 | |
Non-Current Investments | 15,209.56 | 13,393.43 | 8,221.77 | 6,584.35 | 4,880.89 | |
Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Long Term Loans And Advances | 1,654.32 | 1,429.47 | 2,601.15 | 828.43 | 401.52 | |
Other Non-Current Assets | 535.45 | 540.14 | 460.50 | 542.08 | 321.76 | |
Total Non-Current Assets | 19,823.66 | 17,914.85 | 15,210.01 | 11,765.84 | 10,811.13 | |
CURRENT ASSETS | ||||||
Current Investments | 0.01 | 0.01 | 0.01 | 0.01 | 129.04 | |
Inventories | 2,359.28 | 2,367.60 | 4,125.26 | 3,356.18 | 4,841.38 | |
Trade Receivables | 4,195.05 | 3,776.59 | 4,560.26 | 3,973.24 | 5,928.01 | |
Cash And Cash Equivalents | 298.36 | 94.34 | 132.14 | 50.78 | 386.18 | |
Short Term Loans And Advances | 5.44 | 4.60 | 7.99 | 8.97 | 12.03 | |
OtherCurrentAssets | 831.26 | 995.99 | 897.98 | 2,445.93 | 1,081.22 | |
Total Current Assets | 7,689.40 | 7,239.13 | 9,723.64 | 9,835.11 | 12,377.86 | |
Total Assets | 27,513.06 | 25,153.98 | 24,933.65 | 21,600.95 | 23,188.99 | |
OTHER ADDITIONAL INFORMATION | ||||||
CONTINGENT LIABILITIES, COMMITMENTS | ||||||
Contingent Liabilities | 1,329.98 | 2,053.57 | 596.69 | 277.61 | 1,337.36 | |
CIF VALUE OF IMPORTS | ||||||
Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Stores, Spares And Loose Tools | 1,583.90 | 3,330.78 | 3,805.98 | 2,796.47 | 4,061.48 | |
Trade/Other Goods | 1,583.90 | 3,330.78 | 3,805.98 | 2,796.47 | 4,061.48 | |
Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
EXPENDITURE IN FOREIGN EXCHANGE | ||||||
Expenditure In Foreign Currency | 402.07 | 483.04 | 338.75 | 355.90 | 433.08 | |
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
EARNINGS IN FOREIGN EXCHANGE | ||||||
FOB Value Of Goods | 9,161.52 | 9,534.20 | 8,370.34 | 7,286.22 | 13,324.78 | |
Other Earnings | 62.08 | 294.80 | 177.99 | 438.29 | 19.91 | |
BONUS DETAILS | ||||||
Bonus Equity Share Capital | 46.55 | 46.55 | 46.55 | 46.55 | 46.55 | |
NON-CURRENT INVESTMENTS | ||||||
Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
Non-Current Investments Unquoted Book Value | 15,209.56 | 13,393.43 | 8,221.77 | 6,584.35 | 4,880.89 | |
CURRENT INVESTMENTS | ||||||
Current Investments Quoted Market Value | 0.01 | 0.01 | 0.01 | 0.01 | 100.04 | |
Current Investments Unquoted Book Value | -- | -- | -- | -- | 29.00 |
09.10.2025
11.09.2025
Aurobindo Pharma shares rise 4.5% as report says GTCR strikes $4.8-bn deal to buy Zentiva
08.09.2025
Aurobindo Pharma shares fall on eight observations from USFDA
08.09.2025
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
27.05.2025
Aurobindo Pharm Standalone March 2025 Net Sales at Rs 2,731.99 crore, down 5.6% Y-o-Y
12.02.2025
Aurobindo Pharm Standalone December 2024 Net Sales at Rs 2,916.63 crore, up 8.34% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL